Clinical study on oral-health management in sustaining the condition of inflammatory bowel disease patients in remission

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K19339
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 57080:Social dentistry-related
• Research Institution: Tsurumi University
• Principal Investigator: Otsuka Ryoko 鶴見大学, 歯学部, 非常勤講師 (00803701)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 炎症性腸疾患 / 口腔保健管理 / 次世代シークエンス解析 / 唾液カルプロテクチン / ELISA

Outline of Final Research Achievements

A chronic immune-mediated inflammatory disease of the gastrointestinal tract known as inflammatory bowel disease (IBD) is being widely investigated with growing attention for possible involvement of oral pathogens. This study focused on the effects of a progressive oral-health care on the conditions of IBD patients in remission comparing with healthy volunteers. In addition, salivary calprotectin; a calcium-binding antimicrobial protein complex was targeted aiming to assess the inflammatory activity in IBD patients to monitor disease activity as a biomarker instead of fecal calprotectin.
It was indicated that a progressive oral-health management including self-oral care using a custom-tray and hypochlorous acid electrolyzed water (twice a day) contributes to the improvement of the oral environment of IBD patients in remission. Salivary calprotectin might be a useful marker for monitoring IBD disease state.

Free Research Field

社会歯学

Academic Significance and Societal Importance of the Research Achievements

炎症性腸疾患（IBD）は、再燃と寛解を繰り返す病態であるため、寛解期が長く続けば患者の生活の質は上がり、負担も大きく軽減される。そのためには継続的な病態把握が可能なマーカーの探索は必要不可欠である。本研究で採用した唾液カルプロテクチンはすでに保険収載されている便中カルプロテクチンと同様の傾向を示した。得られた知見は、今後のIBDバイオマーカ―を対象とした臨床研究に寄与することが考えられる。